Diabetic cardiomyopathy:Emerging therapeutic options  

作　　者：Cornelius James Fernandez Sahana Shetty Joseph M Pappachan 

机构地区：[1]Department of Endocrinology&Metabolism,Pilgrim Hospital,United Lincolnshire Hospitals NHS Trust,Boston PE219QS,United Kingdom [2]Department of Endocrinology,Kasturba Medical College,Manipal Academy of Higher Education,Manipal 576104,Karnataka,India [3]Department of Endocrinology and Metabolism,Lancashire Teaching Hospitals NHS Trust,Preston PR29HT,United Kingdom [4]Faculty of Science,Manchester Metropolitan University,Manchester M156BH,United Kingdom [5]Faculty of Biology,Medicine and Health,The University of Manchester,Manchester M139PL,United Kingdom

出　　处：《World Journal of Diabetes》2024年第8期1677-1682,共6页世界糖尿病杂志（英文版）（电子版）

摘　　要：Diabetic cardiomyopathy(DbCM)is a common but underrecognized complication of patients with diabetes mellitus(DM).Although the pathobiology of other cardiac complications of diabetes such as ischemic heart disease and cardiac autonomic neuropathy are mostly known with reasonable therapeutic options,the mechanisms and management options for DbCM are still not fully understood.In its early stages,DbCM presents with diastolic dysfunction followed by heart failure(HF)with preserved ejection fraction that can progress to systolic dysfunction and HF with reduced ejection fraction in its advanced stages unless appropriately managed.Apart from prompt control of DM with lifestyle changes and antidiabetic medications,disease-modifying therapy for DbCM includes prompt control of hypertension and dyslipidemia inherent to patients with DM as in other forms of heart diseases and the use of treatments with proven efficacy in HF.A basic study by Zhang et al,in a recent issue of the World Journal of Diabetes elaborates the potential pathophysiological alterations and the therapeutic role of teneligliptin in diabetic mouse models with DbCM.Although this preliminary basic study might help to improve our understanding of DbCM and offer a potential new management option for patients with the disease,the positive results from such animal models might not always translate to clinical practice as the pathobiology of DbCM in humans could be different.However,such experimental studies can encourage more scientific efforts to find a better solution to treat patients with this enigmatic disease.

关 键 词：Diabetic cardiomyopathy Diabetic cardiomyopathy Heart failure PATHOBIOLOGY Teneligliptin 

分 类 号：R587.2[医药卫生—内分泌] R542.2[医药卫生—内科学]